Precipio, Inc. (PRPO) News
Filter PRPO News Items
PRPO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PRPO News Highlights
- PRPO's 30 day story count now stands at 3.
- Over the past 28 days, the trend for PRPO's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- CONN and NOV are the most mentioned tickers in articles about PRPO.
Latest PRPO News From Around the Web
Below are the latest news stories about PRECIPIO INC that investors may wish to consider to help them evaluate PRPO as an investment opportunity.
Precipio Management Shares Thoughts on 2023, and Looks Ahead To 2024NEW HAVEN, Conn., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) shares thoughts and reflections looking back at 2023, and forward to 2024. At the start of 2023, management set three goals, all focused on achieving cash flow breakeven going forward: Target #1: For the pathology division, reaching estimated annualized revenues of $14M, which was expected to enable the division to achieve cash flow breakeven based on its cost stru |
Precipio Announces Q3-2023 Shareholder Update CallConference Call to be held on November 20th, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), will be hosting its Q3-2023 corporate update call on November 20th, 2023 at 5:00 PM ET. The call will include updates on all of the company’s current core businesses. The conference call may be accessed by calling 844-695-5519 (international callers dial 1-412-902-6760). All callers should ask for the Precipio Inc. |
When Will Precipio, Inc. (NASDAQ:PRPO) Breakeven?Precipio, Inc. ( NASDAQ:PRPO ) is possibly approaching a major achievement in its business, so we would like to shine... |
Precipio to Report $4.5M Q3-2023 Revenues, Double From Q3-202228% Revenue Increase Is Major Step Toward Company BreakevenNEW HAVEN, Conn., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that Q3-2023 (unaudited) revenues have increased 28% to $4.5M from $3.5M in Q2-2023, and have more than doubled from $2.2M from Q3-2022. The combination of ongoing revenue growth in both the pathology and products divisions, alongside efficiency and cost reduction initiatives has rapidly moved the company towa |
Precipio’s Q3 Cash Burn From Operations (unaudited) Declines 59% YoY, from $2.5M in Q3-2022 to approximately $1M in Q3-2023Company anticipates current cash levels sufficient to reach breakevenNEW HAVEN, Conn., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces that the combination of revenue growth and cost cutting initiatives has reduced Cash Burn From Operations (CBFO) by 59% compared to the same quarter last year, from approximately $2.5M/quarter to $1M/quarter. Management has set a target of reaching financial independence with its current cash reserve |
Precipio Continues to Sign New HemeScreen™ CustomersNew customer orders received in Q3 exceed $1M annualized revenueNEW HAVEN, Conn., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that new customer orders are expected to bring total Q4 HemeScreen revenues to an estimated $1.2M. In a recent announcement, the company announced that the product revenue necessary to reach cash flow breakeven has been reduced to $6M annualized run rate, or $1.5M/quarter. As of today, Precipio forecasts |
Precipio Reduces Product Revenue Result Needed for Cash Flow BreakevenHigher pathology revenues and lower cost structure drive down product revenue breakeven point from $8M to $6MNEW HAVEN, Conn., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced that due to the increased pathology revenue, and the recent operational efficiencies, the company has reduced the revenue required from the products division to reach breakeven from $8M to $6M annually, or $1.5M per quarter, 25% below previous estimates. This m |
Precipio Takes Final Step Towards Regaining Nasdaq ComplianceCompany announces 1-for-20 reverse stock splitNEW HAVEN, Conn., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) today announced that it has implemented a 1-for-20 reverse stock split of outstanding shares of the company's common stock in order to regain compliance with the Nasdaq minimum bid price requirement of $1.00. What is the economic impact to you, the shareholder? A reverse split essentially means a decrease in the number of shares and |
Precipio’s Pathology Division Exceeds Breakeven Revenues in August, Four Months Ahead of PlanCompany continues to make strides towards profitabilityNEW HAVEN, Conn., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), announces its Pathology Division has in August exceeded the monthly breakeven revenue goal which, if continued, causes this division to contribute cash to the Company’s operations. As previously announced, the revenue target for pathology division breakeven is an annualized run rate of $14M, which is equivalent to approxim |
11 ChatGPT Penny Stock PicksIn this article, we will take a look at the 11 ChatGPT penny stock picks. To see more such companies, go directly to 5 ChatGPT Penny Stock Picks. The AI boom that started with the launch of ChatGPT from OpenAI seems to have no end in sight. A McKinsey report compared the fickle rise of […] |